{"title": "PDF", "author": "PDF", "url": "https://previous.revmexneurociencia.com/wp-content/uploads/2014/05/Nm111-02.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Rev Mex Neuroci 2011 ; 12(1): 8-15 Alva Moncayo E, et al. Recomendaciones en epilepsia parcial con oxcarbazepina8 Recomendaciones y aplicaci\u00f3n cl\u00ednica en el tratamiento de la epilepsia parcial con oxcarbazepina. Encuesta Nacional de Neur\u00f3logos Mexicanos Alva Moncayo Edith,* L\u00f3pez Ru\u00edz Minerva,** Rogel Ortiz Francisco Javier,** Sevilla Castillo Ricardo A,** G\u00f3mez Placencia y Castillo Jes\u00fas,** Rodr\u00edguez Leyva Ildefonso,** Rodr\u00edguez Ku Ren\u00e9 Jes\u00fas,** Su\u00e1stegui Rom\u00e1n Roberto A,** Espinoza Montero Rub\u00e9n,** Genel Castillo Mario Alberto,** Montoya Salazar Jos\u00e9 Guadalupe,** Guti\u00e9rrez Moctezuma Juvenal** * Coordinadora general del consenso. ** Coordinadores regionales del consenso. RESUMENAntecedentes y objetivo: Las epilepsias identifican dos grandes etiolog\u00edas gen\u00e9ticas o adquiridas. En lasgen\u00e9ticas: a) Por anomal\u00edas en canales i\u00f3nicos queintervienen en la excitabilidad neuronal. b) Alteracio- nes del metabolismo neuronal y c) Alteraciones en la migraci\u00f3n neuronal. Algunos tipos de epilepsia, seaprimaria o resistente al tratamiento farmacol\u00f3gico,requiere del inicio de nuevos antiepil\u00e9pticos incluidala oxcarbazepina. Introducido por primera vez enM\u00e9xico desde su comercializaci\u00f3n mundial, requeri- mos comparar la prescripci\u00f3n con las revisiones de organizaciones internacionales en epilepsias parcia-les de reciente diagn\u00f3stico y refractarias. Material y m\u00e9todos: Se llev\u00f3 a cabo encuesta aplicada a m\u00e9- dicos de 35 ciudades de diversas regiones de M\u00e9xi-co, consistente en cuestionario de 20 preguntas de opci\u00f3n m\u00faltiple. Mediante 11 coordinadores regio- nales distribuidos en ocho regiones se recab\u00f3 la infor-maci\u00f3n y los cuestionarios contestados. Una vez ob-tenida la informaci\u00f3n demogr\u00e1fica de los pacientesepil\u00e9pticos atendidos, y en particular de la epilepsiaparcial tratada con oxcarbazepina, se procedi\u00f3 a analizar los datos en forma individual, regional y ge- neral. Resultados: La encuesta se aplic\u00f3 a 306 m\u00e9di- cos: 146 neur\u00f3logos (48%), 81 neuropediatras of seizures it became necessaryto know its usefulness and contrast it to the international regulations. Methodology: A 20-option questionnaire was answered by the 11 regionalcoordinators who were distributed in 8 areas. Properdemographic information from epileptic patientstreated with oxcarbazepine was added to the resultsin order to be analyzed in an individual and general manner. Results: 306 doctors from 35 cities answered neurologists (48%), 81neuropaediatricians (26%), 60 neurosurgeons (19.6%),CONTRIBUCI\u00d3N ORIGINAL INTRODUCCI\u00d3N La epilepsia contin\u00faa siendo un problema de sa- lud p\u00fablica a pesar de los avances terap\u00e9uticos, cuyoobjetivo del tratamiento es el control total de lascrisis; sin embargo, existen errores diagn\u00f3sticosincluyendo la falta de identificaci\u00f3n temprana. Enel caso de las crisis parciales son el tipo de epilep-sia predominante. Las epilepsias identifican dos grandes etiolog\u00edas gen\u00e9ticas o adquiridas. En las gen\u00e9ticas puede ha-ber:\u007f Una anomal\u00eda en los canales i\u00f3nicos que intervie- nen en la excitabilidad de las neuronas como lascanalopat\u00edas. \u007f Alteraciones del metabolismo que influyan en la estructura y la funci\u00f3n de las neuronas. \u007f Alteraciones en la migraci\u00f3n neuronal. En las epilepsias adquiridas hay una lesi\u00f3n originada por traumatismos, infecciones, alteraciones cerebrovasculares,tumores o enfermedades degenerativas 1-3 que sola o debi- da a un sustrato gen\u00e9tico, provoca cambios en las neuronasdel foco que aumentan su excitabilidad, lo que haceRevista Mexicana de Neurociencia Enero-Febrero, 2011; 12(1): 8-15Rev Mex Neuroci 2011 ; 12(1): 8-15 Alva Moncayo E, et al. Recomendaciones en epilepsia parcial con oxcarbazepina9 neurocirujanos (19.6%) y 19 de otras especialidades (6.4%). El total de pacientes epil\u00e9pticos atendidos porlos m\u00e9dicos fue de 21,476 y de \u00e9stos 12,646 correspon- dieron a crisis parciales correspondiente a 58.8%. En las crisis parciales la primera elecci\u00f3n en el trata-miento fue la oxcarbazepina, seguida de lacarbamazepina y \u00e1cido valproico. La remisi\u00f3n delas crisis las obtienen en 78.8% de los casos y la dura-ci\u00f3n del tratamiento prescrito por sus m\u00e9dicos fue de 3-5 a\u00f1os en 69.3% y s\u00f3lo 10.5% nunca lo suspende. Conclusi\u00f3n: La oxcarbazepina es una alternati- va como opci\u00f3n de tratamiento por expertos neur\u00f3-logos mexicanos en el control de la epilepsia parcial. Palabras clave: Oxcarbazepina, epilepsia parcial, monoterapia, epileptic (58%) treated with valproic acid. Crisis control is reached in 78.8%. A 3 to 5-yeartreatment is 69.3% and only considered by most Mexicanneurologists. Its length was similar to those reported in medical literature but given in minor doses. The collateral effects were minimal parox\u00edstica e hipersincr\u00f3nica. Esta transformaci\u00f3n de un \u00e1rea deneuronas normales en un foco con neuronashiperexcitables se llama epileptog\u00e9nesis. En algunostipos de epilepsia se desarrollan mecanismos de re-sistencia que hacen que la epilepsia sea primaria ose vuelva resistente al tratamiento farmacol\u00f3gico.Debido a estos factores se inicia la era de los nuevosantiepil\u00e9pticos donde surge la oxcarbazepina (OXC),antiepil\u00e9ptico introducido por primera vez enLatinoam\u00e9rica y particularmente en M\u00e9xico en lad\u00e9cada de los 80 del siglo XX. Por lo tanto, se cuentauna experiencia en sus indicaciones y aplicaci\u00f3n enel campo de la epilepsia, motivo por el que surge lanecesidad de dar a conocer la experiencia en neur\u00f3-logos mexicanos sobre la utilidad y aplicaciones de laoxcarbazepina en epilepsia y compararla con loslineamientos internacionales establecidos por la ILAE,AAE, AAN, NICE 4-7 y CAMELICE, considerando el tiempo tan prolongado que tiene en el mercado mexicanoesta droga. La oxcarbazepina (10,11-dihidro-10-oxo-5H- dibenzazepina-5 carbamida) es la 10-ceto con actividad antiepil\u00e9ptica. Laoxcarbazepina es transformada r\u00e1pidamente por 10-hidroxi-carbazepina la que tiene una vida media m\u00e1slarga y alcanza de 20 a 50% m\u00e1s la concentraci\u00f3nplasm\u00e1tica cuando se administra la oxcarbazepina, yno tiene propiedades de autoinducci\u00f3n. 8-10 La seguridad y tolerabilidad en ni\u00f1os menores de cuatro a\u00f1os con epilepsia parcial refractaria se re-portan en dos estudios piloto como monoterapia o te-rapia de adici\u00f3n. La OXC es un medicamentoantiepil\u00e9ptico indicado en crisis parciales comomonoterapia o terapia de adici\u00f3n en ni\u00f1os y adul- tos. 11-14 La seguridad y eficacia de la OXC como monoterapia de primera l\u00ednea en ni\u00f1os entre 5-17a\u00f1os se ha demostrado con estudios aleatorios, do-ble ciego comparativo con fenito\u00edna (PTH), siendolas dosis utilizadas de mg/kg/d\u00eda dosis de fenito\u00edna 5.8 mg/kg/d\u00eda. La propor-ci\u00f3n de pacientes libres de crisis en estudios de se-guimiento de 48 semanas fue similar en los pacien-tes que recibieron OXC vs. PHT, pero con cambios satisfactorias de la OXC en la tolerabilidad consignificancia estad\u00edstica (P = 0.002). 15 Otro estudio comparativo entre oxcarbazepina y valproato en 249 pacientes entre 15 y 65 a\u00f1os a dosisde 900 a 2,400 mg mostrando remisi\u00f3n de crisis en57% con la administraci\u00f3n de oxcarbazepina vs. 54% con valproato, sin existir diferencias en reaccionesadversas. La oxcarbazepina ha acumulado al cabo deltiempo m\u00e1s de 200,000 pacientes a\u00f1o tratados, yasea para tratamiento de inicio o de adici\u00f3n en el tra-tamiento de crisis parciales, con excelentetolerabilidad y con reducci\u00f3n del riesgo deinteracciones en comparaci\u00f3n con los antiepil\u00e9pticosconvencionales. 16-20 Este trabajo tiene el prop\u00f3sito de proponer reco- mendaciones para la epilepsia como primera l\u00edneade antiepil\u00e9pticos basado en las recientes revi-siones sobre este t\u00f3pico, pero sobre todo dar aconocer la informaci\u00f3n recopilada por expertosneur\u00f3logos en epilepsia. Asimismo, tiene el prop\u00f3- sito de revisar las indicaciones, dosis administradas,contraindicaciones, posibles asociaciones con otrasdrogas antiepil\u00e9pticas y reacciones secundarias a queRev Mex Neuroci 2011 ; 12(1): 8-15 Alva Moncayo E, et al. Recomendaciones en epilepsia parcial con oxcarbazepina10 se han enfrentado sus pacientes con la administra- ci\u00f3n de oxcarbazepina en epilepsias parciales y re-fractarias en la poblaci\u00f3n mexicana pedi\u00e1trica y deadultos, en particular en el embarazo y con presen-cia de comorbilidades. Se propondr\u00e1 establecer unaruta cr\u00edtica mediante un flujograma donde exista unabordaje diagn\u00f3stico y terap\u00e9utico que permita es-tablecer la primera elecci\u00f3n en las epilepsias parcia-les de diagn\u00f3stico reciente o refractarias, conside-rando las experiencias y resultados observados porneur\u00f3logos mexicanos. MATERIAL Y M\u00c9TODOS El estudio corresponde a una encuesta consisten- te en un cuestionario de 20 peguntas de opci\u00f3nm\u00faltiple que se aplic\u00f3 a 306 m\u00e9dicos que tratan pa-cientes con epilepsia: 146 neur\u00f3logos (48%), 81neuropediatras (26%), 60 neurocirujanos y 19de otras especialidades (6.4%). Se seleccionaron 11 coordinadores, distribuidos en ocho regiones que comprendieron a las siguien-tes 35 ciudades de la Rep\u00fablica Mexicana: \u007f Regi\u00f3n 1. Cuernavaca, Distrito Federal, Toluca, Pachuca y Acapulco. \u007fRegi\u00f3n 2. Monterrey, Tampico y Reynosa \u007fRegi\u00f3n 3. Tijuana, Mexicali, Culiac\u00e1n, Ciudad Obreg\u00f3n, y Hermosillo \u007fRegi\u00f3n 4. Ciudad Ju\u00e1rez, Chihuahua, Durango y Torre\u00f3n \u007fRegi\u00f3n 5. Guadalajara, Morelia, Aguascalientes y Sonora \u007fRegi\u00f3n 6. Celaya, Quer\u00e9taro, Le\u00f3n y San Luis Po- tos\u00ed \u007fRegi\u00f3n 7. Puebla, Veracruz, Coatzacoalcos, C\u00f3rdoba y Jalapa. \u007fRegi\u00f3n 8. M\u00e9rida, Tuxtla Guti\u00e9rrez Chiapas, Canc\u00fan, Villahermosa, Oaxaca. Una vez obtenida la informaci\u00f3n y reunidos los cuestionarios, se analiz\u00f3 la informaci\u00f3n demogr\u00e1ficade los pacientes, particularmente de aqu\u00e9lloscon epilepsia parcial de inicio reciente, y trata-dos con ox carbazepina. La informaci\u00f3n recopiladas en una hoja Excel y se evalu\u00f3 en forma individual,regional y general. Los resultados se recopilaron porcada pregunta que se fue planteando y por tipo deespecialista que lo contesto, as\u00ed como de acuerdocon el tratamiento farmacol\u00f3gico indicado comomonoterapia o terapia de adici\u00f3n. Particularmenteel uso de la oxcarbazepina en M\u00e9xico y los efectossecundarios que se presentan en su prescripci\u00f3n desde el tiempo total de su experiencia m\u00e9dica, y lacomercializaci\u00f3n del producto en M\u00e9xico para la epi-lepsia. Los resultados fueron concentrados en esta-d\u00edsticas descriptivas, con base en medidas de ten-dencia central, por gr\u00e1ficas y tablas. Los resultados finales se dieron a conocer a todos los coordinadores, para ser difundidos a la comuni-dad m\u00e9dica, donde se incluyeron las opiniones detodos los expertos que atienden al paciente epil\u00e9p-tico en M\u00e9xico, y dar a conocer el cuestionario y lasconclusiones de dicha revisi\u00f3n. RESULTADOS El total de pacientes atendidos por los m\u00e9dicos encuestados fue de 55,396, distribuidos en una pro-porci\u00f3n de 100 a 400 por mes por cada m\u00e9dicoencuestado ( Figura 1 ). El 35.3% de los m\u00e9dicos atien- de de 0 a 100 pacientes al mes, en tanto que 65.7%atiende de 100 a 400 pacientes al mes. El total depacientes epil\u00e9pticos atendidos fue de 21,476, quecorresponde a 39% del total de la consulta reporta-da. De este grupo, 12,646 presentaban crisis parcia-les que corresponde a 58.8% del total de portadoresde epilepsia. Los adultos portadores de epilepsia par-cial representan 36% y el resto corresponden a pa-cientes pedi\u00e1tricos, distribuidos a su vez, en dife-rentes grupos de edad como muestra la tabla 1 . El tratamiento de primera elecci\u00f3n prescrito por los m\u00e9dicos encuestados fue la oxcarbazepina (OXC),seguida por la carbamazepina y el \u00e1cido valproico,como se muestra en la figura 2 y sin diferencias entre las di versas regiones del pa\u00eds analizadas ( Figu- ra 3). En casi 50% de los casos, la elecci\u00f3n en epilep- sia parcial como monoterapia se utiliza laoxcarbazepina (OXC). En contraste con el resto divi-dido como terapia de adici\u00f3n o cuando no es \u00fatilotro esquema de tratamiento inicial el cambio sur-ge pensando en la OXC como lo muestra la tabla 2. En cuanto a la dosis utilizada en forma inicial fue entre300 a 1,200 mg y la de mantenimiento de 600-1,800mg dosis total por d\u00eda ( Tablas 3 y 4 ). Los m\u00e9dicos no solicitan niveles del medicamento en 57.2%, y logran remisi\u00f3n de las crisis entre 50-75%y hasta en 78.8% de los casos atendidos por los neur\u00f3-logos. Al decidir cambiar el tratamiento previo porfalta de control de las crisis, lo fue por la oxcarbazepinapara lograr control de las crisis obteniendo una mejo-r\u00eda con dicho cambio en 68.9% de los casos. La expe-riencia que tienen los m\u00e9dicos encuestados con laprescripci\u00f3n de oxcarbazepina oscila entre cinco a 15Rev Mex Neuroci 2011 ; 12(1): 8-15 Alva Moncayo E, et al. Recomendaciones en epilepsia parcial con oxcarbazepina11 a\u00f1os en m\u00e1s de 80%, relacionado con el inicio de dis- tribuci\u00f3n en M\u00e9xico (Tabla 5) . Existe 33.7% de pacientes en quienes modifica- ron los tratamientos previos por oxcarbazepina, lo-grando el control de las crisis en 68.9% del total decasos, en contraste como terapia de adici\u00f3n en 39.5%.En relaci\u00f3n con la politerapia, el antiepil\u00e9ptico deelecci\u00f3n como complemento de la oxcarbazepina fueel \u00e1cido valproico en 48.6%. En estos casos la dosispromedio fue semejante a la dosis inicial utilizadacomo monoterapia inicial. Las reacciones secundarias detectadas con m\u00e1s frecuencia fueron la somnolencia y mareo en 38.3 y21.6%, respectivamente, mientras que lahiponatremia se report\u00f3 s\u00f3lo en 9.2%, ameritando la suspensi\u00f3n del f\u00e1rmaco s\u00f3lo en 5% de los casos. El tiempo de instauraci\u00f3n del tratamiento es de 3-5 a\u00f1os en 69.3% de los m\u00e9dicos y s\u00f3lo 10.5% nunca TTTTTabla 1abla 1abla 1abla 1abla 1 Grupos de estudio de pacientes portadores de epilepsiaGrupos de estudio de pacientes portadores de epilepsiaGrupos de estudio de pacientes portadores de epilepsiaGrupos de estudio de pacientes portadores de epilepsiaGrupos de estudio de pacientes portadores de epilepsia parcialparcialparcialparcialparcial Tipo de paciente Total de pacientes % de pacientes Lactantes 1,019 9 Preescolares 1,693 13 Escolares 2,639 Total 12,646 100aaaaaaaaaaaa aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa /i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15 aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa a a a a a a a a a a a a a a a a a a a4.90% 7.84% 19.61% 32.35%35.29% 0 a100 /i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15101 a 200 201 a 300aaaaaaaaaaaaaaaaaa 301 a 400 401 a 500 Figura 1.Figura 1.Figura 1.Figura 1.Figura 1. Proporci\u00f3n de pacientes atendidos de la consulta de neurolog\u00eda en M\u00e9xico. aaaaaaaaaaaaaaa/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15 aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa a a aaaa a a aaaaaaaaaaaaaaaaaaOxcarbazepina Lamotrigina Figura 2. Figura 2. Figura 2. Figura 2. Figura 2. Medicamentos prescritos como de primera elecci\u00f3n en epilepsia parcial en poblaci\u00f3n mexicana.0.69%13.89% aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa a a a aCarbamezepina /i15/i15/i15/i15/i15/i15/i15/i15/i15/i15Topiramato No contest\u00f3Otro aaaaaaaaaaaaaaaOtro a a aaaaaaaaaaaaaaaaaaNo contest\u00f3 Topiramato Figura 3. Figura 3. Figura 3. Figura 3. Figura 3. Tratamiento de oxcarbazepina de primera elecci\u00f3n por regiones en M\u00e9xico.aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa aaaaCarbamazepina /i15/i15/i15/i15/i15/i15/i15/i15/i15/i15Lamotrigina aaa aaa aaa aaaaaaaaaaaaaa a aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa a a a a a aaaaaaa aaa aaa aaa aaaaaaaa aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa a a a a a aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa aaaaaaa aaa aaaaaaaaaaaaaa aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa a a aaaaaaaaaaaaa a /i15/i15/i15/i15/i15/i15 /i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15 /i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15Segmentaci\u00f3n de tratamiento por regi\u00f3n % 100 90 80 70 60 50 40 30 20 12(1): 8-15 Alva Moncayo E, et al. Recomendaciones en epilepsia parcial con oxcarbazepina12 suspendi\u00f3 el tratamiento establecido para la epilep- sia parcial. Un punto de gran impacto en el conoci-miento y la aplicaci\u00f3n del tratamiento de la epilepsiaparcial con oxcarbazepina es que m\u00e1s de 80% de losm\u00e9dicos encuestados tiene utiliz\u00e1ndolo de 5-10 lo que da un valor significativo en la experiencia de la aten-ci\u00f3n del paciente epil\u00e9ptico mexicano. DISCUSI\u00d3N Las f\u00e1rmacos antiepil\u00e9pticos actuales previenen las crisis en aproximadamente 33% de los pacientestratados y aproximadamente la mitad de ellos sonportadores de epilepsia parcial simple, compleja, osecundariamente generalizada. No obstante son cau-santes de eventos adversos variados a nivel hep\u00e1ti-co, renal, \u00f3seo, supresi\u00f3n de m\u00e9dula \u00f3sea, depresordel sistema nervioso central, etc. Resulta necesario conocer la relaci\u00f3n riesgo-be- neficio de los antiepil\u00e9pticos convencionales y de losnuevos antiepil\u00e9ptico. Aunque hasta el momento noexiste el antiepil\u00e9ptico ideal, requerimos que la pres-cripci\u00f3n e indicaci\u00f3n sea espec\u00edfica dependiendo delpatr\u00f3n cl\u00ednico de crisis y particularmente el manejode monoterapia. Diversos estudios han mostrado que la oxcarbazepina con dosis diarias de 15-20 mg o suequivalente en dosis total entre 900 y 1,200 mg dia-rios en ni\u00f1os o adultos, como lo describenGuerreiro 3 y Schachter19 quienes observaron que la eficacia comparada con antiepil\u00e9pticos est\u00e1ndareso convencionales fue mejor. En esta encuesta se observa claramente que la oxcarbazepina es de pri-mera elecci\u00f3n en pacientes con diagn\u00f3stico recien-te de epilepsia parcial y en los casos en donde la res-puesta no es eficaz a los tratamientos previosincluidos los nuevos antiepil\u00e9pticos, por lo que deci-den la modificaci\u00f3n con OXC con control de las crisisen m\u00e1s de 50% de los casos, sean ni\u00f1os o adultos. En el consenso realizado por Schmidt, 2 se reco- mienda la monoterapia con OXC como primera elec-ci\u00f3n en epilepsias parciales y que la modificaci\u00f3n conOXC cuando se utilizan otros antiepil\u00e9pticos se reco-miendan dosis iniciales en ni\u00f1os de 8-10 mg/kg/d\u00eda,dividida en dos o tres dosis al d\u00eda, y dosis m\u00e1xima deTTTTTabla 4abla 4abla 4abla 4abla 4 Dosis de mantenimiento durante todo el tiempo que seDosis de mantenimiento durante todo el tiempo que seDosis de mantenimiento durante todo el tiempo que seDosis de mantenimiento durante todo el tiempo que seDosis de mantenimiento durante todo el tiempo que se instal\u00f3 el tratamiento en el tiempo establecidoinstal\u00f3 el tratamiento en el tiempo establecidoinstal\u00f3 el tratamiento en el tiempo establecidoinstal\u00f3 el tratamiento en el tiempo establecidoinstal\u00f3 el tratamiento en el tiempo establecido Dosis Frecuencia % 5-30 mg/kg/d\u00eda 122 39.9 31-50mg/kg/d\u00eda 42 13.7 < 300 mg diarios 4 1.3 300-1,200 mg diarios 33 10.8 No clasificable 13 4.2 No contest\u00f3 92 30.1 Total 306 100TTTTTabla 2abla 2abla 2abla 2abla 2 Momento del uso de la oxcarbazepina como monoterapiaMomento del uso de la oxcarbazepina como monoterapiaMomento del uso de la oxcarbazepina como monoterapiaMomento del uso de la oxcarbazepina como monoterapiaMomento del uso de la oxcarbazepina como monoterapia Momento en que se indic\u00f3 la OXC Frecuencia % indicaci\u00f3n Porcentaje acumulado Monoterapia Inicial 214 48.6 48.6 Terapia de adici\u00f3n 80 18.2 66.8 Por falla en tratamiento inicial 82 18.6 85.5 Por efectos secundarios de otros FAE 'S 61 13.9 99.3 No contest\u00f3 3 0.7 100 Total 440 100 TTTTTabla 3abla 3abla 3abla 3abla 3 Margen de dosis inicial utilizada en la poblaci\u00f3n conMargen de dosis inicial utilizada en la poblaci\u00f3n conMargen de dosis inicial utilizada en la poblaci\u00f3n conMargen de dosis inicial utilizada en la poblaci\u00f3n conMargen de dosis inicial utilizada en la poblaci\u00f3n con diagn\u00f3stico de epilepsia parcialdiagn\u00f3stico de epilepsia parcialdiagn\u00f3stico de epilepsia parcialdiagn\u00f3stico de epilepsia parcialdiagn\u00f3stico de epilepsia parcial Dosis Frecuencia % 5-30 mg/kg/d\u00eda 169 55.2 31-50 mg/kg/d\u00eda 9 2.9 < 300 mg 7 2.3 300-600 mg/d\u00eda 23 7.5 No clasificable 11 3.6 No contest\u00f3 87 28.4 Total 306 100 TTTTTabla 5abla 5abla 5abla 5abla 5 TTTTTiempo de experiencia de m\u00e9dicos mexicanos en eliempo de experiencia de m\u00e9dicos mexicanos en eliempo de experiencia de m\u00e9dicos mexicanos en eliempo de experiencia de m\u00e9dicos mexicanos en eliempo de experiencia de m\u00e9dicos mexicanos en el tratamiento de la epilepsia parcial con oxcarbazepinatratamiento de la epilepsia parcial con oxcarbazepinatratamiento de la epilepsia parcial con oxcarbazepinatratamiento de la epilepsia parcial con oxcarbazepinatratamiento de la epilepsia parcial con oxcarbazepina Tiempo en a\u00f1os Frecuencia Porcentaje Hace 5 a\u00f1os 127 41.5 Hace 10 a\u00f1os 124 40.5 Hace 15 a\u00f1os 51 16.7 No contesto 4 1.3 Total 306 100Rev Mex Neuroci 2011 ; 12(1): 8-15 Alva Moncayo E, et al. Recomendaciones en epilepsia parcial con oxcarbazepina13 30-46 mg/kg/d\u00eda, con bajo potencial de interacciones farmacol\u00f3gicas y mejor tolerabilidad que losantiepil\u00e9pticos convencionales. Este estudio es rele-vante considerando que quienes contestaron el cues-tionario fueron m\u00e9dicos neur\u00f3logos mexicanos conun experiencia m\u00ednima de 5-10 a\u00f1os en el \u00e1rea, y porsupuesto dentro de su poblaci\u00f3n de atenci\u00f3nneurol\u00f3gica corresponde a poco m\u00e1s de 50% de ca-sos portadores de alg\u00fan tipo de epilepsia. Conclu-yendo que la oxcarbazepina es una alternativa comoopci\u00f3n de tratamiento de primera elecci\u00f3n a dosisterap\u00e9uticas recomendadas en la literatura y aplica-das en este grupo encuestado, y con control de cri-sis en un poco m\u00e1s de 80%, sin reacciones adversasque ameriten la suspensi\u00f3n del tratamiento estable-cido. Adem\u00e1s se debe enfatizar que las dosis m\u00e1xi-mas utilizadas para el control no sobrepasan los 2 gpor d\u00eda en el caso del paciente adulto y en elpedi\u00e1trico entre 10-30 mg/kg/d\u00eda para lograr la remi-si\u00f3n de las crisis en m\u00e1s de 75%, a diferencia de loreportado en la literatura. De hecho, la dosis m\u00e1xi-ma utilizada no rebasa los 1,800 mg por d\u00eda durantetodo el tiempo de su administraci\u00f3n entre tres a cin-co a\u00f1os que lleva el tratamiento para decidir la sus-pensi\u00f3n del f\u00e1rmaco como lo describi\u00f3 Dam, 22 y en la poblaci\u00f3n estudiada de epilepsias parciales se obtu-vieron buenos resultados y en consecuencia en m\u00e1sde 80% la suspensi\u00f3n del tratamiento. La oxcarbazepina es una alternativa como opci\u00f3n de tratamiento en nuestra experiencia de neur\u00f3lo-gos mexicanos, sin reacciones adversas que ameritenla suspensi\u00f3n del tratamiento establecido. El tiempototal de su administraci\u00f3n terap\u00e9utica fue de tres acinco a\u00f1os para decidir la suspensi\u00f3n del f\u00e1rmaco. CONCLUSIONES La epilepsia en M\u00e9xico es la segunda causa de atenci\u00f3n m\u00e9dica en la consulta neurol\u00f3gica, resultapor ello indispensable conocer la experiencia de ex-pertos en la atenci\u00f3n integral de paciente con epi-lepsia parcial, y difundir esa informaci\u00f3n a la comu-nidad m\u00e9dica para contar con lineamientosespec\u00edficos que permitan decidir la prescripci\u00f3n es-pec\u00edfica en epilepsia parcial como tratamiento ini-cial y de adici\u00f3n, dosis, duraci\u00f3n del tratamiento yreacciones adversas que deben considerarse comomedidas de precauci\u00f3n. Con la informaci\u00f3n recopilada en la primera en- cuesta nacional del uso de oxcarbazepina en espe-cial podemos concluir lo siguiente en M\u00e9xico y pu-diera ser aplicable en Latinoam\u00e9rica:1. El tratamiento de primera elecci\u00f3n en epilep- sia parcial de diagn\u00f3stico reciente en ni\u00f1os y adul-tos es la oxcarbazepina. 2. Para el paciente adulto la dosis recomendada de mantenimiento es de 1,200 a 1,800 mg diarios frac-cionada en dos tomas. 3. En el caso del paciente pedi\u00e1trico la dosis ad- ministrada es de 10-30 mg/kg/d\u00eda. 4. No ameritan la realizaci\u00f3n de los niveles s\u00e9ricos del f\u00e1rmaco dada la seguridad y eficacia que tiene elf\u00e1rmaco en epilepsias parciales manejado comomonoterapia o terapia de adici\u00f3n. 5. La terapia de adici\u00f3n se tolera adecuadamen- te y puede administrarse gradualmente con la dosisrecomendada como monoterapia, preferentementefenito\u00edna, fenobarbital y Lamotrigina. 6. El tiempo promedio de duraci\u00f3n del tratamien- to para la epilepsia parcial con remisi\u00f3n de las crisises de cinco a\u00f1os. 7. Las reacciones secundarias no ameritan suspen- der el tratamiento, s\u00f3lo determinar si en lamonoterapia o politerapia deben ser asociados conf\u00e1rmacos que no puedan potenciar las reaccionesadversas. 8. Aunque existen otras indicaciones de la oxcarbazepina pueden considerarse para tratar enel mismo paciente estos problemas con buenos re-sultados en su control y disminuir por ende lapoliterapia de tratamientos que en ocasiones limitael control de alguno de los problemas tratados. 9. Se propone la siguiente ruta cr\u00edtica de aborda- je diagn\u00f3stico y terap\u00e9utico en el uso de laoxcarbazepina en epilepsias (Anexos 1 y 2). REFERENCIAS 1. Wellington Keri, Goa LKaren. Oxcarbazepine. Actualization about efficacy in 137-63. 2. Schmidt D, Sachdeo R. of partial epilepsy a 12(1): 8-15 Alva Moncayo E, et al. Recomendaciones en epilepsia parcial con oxcarbazepina14 8. Patsalos PN, Stephenson TJ, Krishna S, Alyas AA, induced 2: 1432. 9. U, H. A double blind controlled clinical 129S-199S. pharmacotherapy 2000; 20(8): 171S-177S. 13. Armijo JA, Valdizan EM, De las Cuevas I, Cuadrado A. Avances en la fisiopatolog\u00eda de la epileptogenesis: aspectos moleculares. Rev Neurol2002; 4-32. 15. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of A double-blind controlled A double-blind 2: 1 neur\u00f3logos a los neur\u00f3logos mexicanosCuestionario aplicado a los neur\u00f3logos mexicanosCuestionario aplicado a los neur\u00f3logos mexicanosCuestionario aplicado a los neur\u00f3logos mexicanos 1. En su ejercicio profesional, en promedio, \u00bfcu\u00e1ntos pacientes atiende usted al mes? 1.1. \u00bfCu\u00e1ntos pacientes atiende usted al mes privados e institucionales? 2. De estos pacientes, en promedio, \u00bfcu\u00e1ntos acuden a atenci\u00f3n por epilepsia? 3. \u00bfCu\u00e1ntos pacientes recibe usted al mes con crisis parciales? P\u00e1gina 6. 4. \u00bfCu\u00e1ntos de estos pacientes que recibe mensualmente con crisis parciales son? 5. \u00bfCu\u00e1l es el tratamiento que considera de primera elecci\u00f3n? 6. \u00bfEn qu\u00e9 momento utiliza oxcarbazepina en crisis parciales? 7. \u00bfDesde cu\u00e1ndo utiliza la oxcarbazepina en crisis parciales? 8. \u00bfQu\u00e9 dosis de inicio utiliza con oxcarbazepina? 9. \u00bfQu\u00e9 dosis de mantenimiento utiliza en oxcarbazepina (en rango)? 10. \u00bfUsted solicita niveles s\u00e9ricos de oxcarbazepina? 11. \u00bfEn qu\u00e9 porcentaje de pacientes logra remisi\u00f3n de las crisis con la administraci\u00f3n de oxcarbazepina como monoterapia? 12. De los pacientes con crisis parciales tratados con otro antiepil\u00e9ptico diferente a oxcarbazepina y que no han logrado un ade cuado control de las crisis \u00bfEn cu\u00e1ntos de ellos modifica tratamiento por monoterapia con oxcarbazepina? 13. De este grupo de pacientes, \u00bfcu\u00e1l es el porcentaje de control de crisis con el cambio? 14. \u00bfEn cu\u00e1ntos de sus pacientes, en lugar de cambiar el tratamiento, decide adicionar oxcarbazepina? 15. \u00bfQu\u00e9 dosis de oxcarbazepina utiliza como tratamiento de adici\u00f3n? 16. \u00bfCon cu\u00e1l f\u00e1rmaco usted considera m\u00e1s \u00fatil adicionar oxcarbazepina? 17. La principal reacci\u00f3n adversa que ha presentado con la administraci\u00f3n de oxcarbazepina es: 18. \u00bfEn qu\u00e9 porcentaje de pacientes ha requerido suspender la oxcarbazepina? 19. La suspensi\u00f3n del tratamiento con oxcarbazepina en los pacientes con remisi\u00f3n de crisis es de: 20. \u00bfEn qu\u00e9 otros tipos de epilepsias utiliza oxcarbazepina? 21. N\u00famero m\u00e1ximo de antiepil\u00e9pticos asociados con la oxcarbazepina que usted emplea.Rev Mex Neuroci 2011 ; 12(1): 8-15 Alva Moncayo E, et al. Recomendaciones en epilepsia parcial con oxcarbazepina15 Anexo 2Anexo 2Anexo 2Anexo 2Anexo 2 Flujograma de abordaje diagn\u00f3stico y terap\u00e9utico en epilepsias parciales con el uso de oxcarbazepinaFlujograma de abordaje diagn\u00f3stico y terap\u00e9utico en epilepsias parciales con el uso de oxcarbazepinaFlujograma de abordaje diagn\u00f3stico y terap\u00e9utico en epilepsias parciales con el uso de oxcarbazepinaFlujograma de abordaje diagn\u00f3stico y terap\u00e9utico en epilepsias parciales con el uso de oxcarbazepinaFlujograma de abordaje diagn\u00f3stico y terap\u00e9utico en epilepsias parciales con el uso de oxcarbazepina Diagn\u00f3stico de epilepsia parcial (aplicar la clasificaci\u00f3n de la lice para un diagn\u00f3stico de precisi\u00f3n) monoterapia Epilepsia parcial Epilepsia parcial, secundariamente generalizada 1\u00aa. L\u00ednea 1\u00aa. L\u00ednea Oxcarbazepina \u00c1cido 10- 30 mg-kg-d\u00eda "}